Mirdametinib and palbociclib for liposarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of liposarcoma called dedifferentiated liposarcoma (DDLPS) that has spread or can't be removed by surgery.
- You need to be 18 or older and able to swallow pills.
- You cannot have had treatment with a selective CDK4 inhibitor (like palbociclib) or a MEK inhibitor (like mirdametinib) before.
- Your kidneys, liver, and heart must be working well enough – your doctor can check this with blood tests and scans.
- You must not have uncontrolled infections, heart problems, or other serious medical conditions that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests a first-line treatment for people with advanced or unresectable dedifferentiated liposarcoma that has spread. The goal is to find a therapy that works before other treatments are used.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Hear when a new Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.